{"id":145644,"date":"2022-09-02T01:33:59","date_gmt":"2022-09-02T01:33:59","guid":{"rendered":"https:\/\/labinsights.com\/acf_article\/%e6%96%b0%e5%85%b4%e8%a1%80%e5%8f%8b%e7%97%85%e7%96%97%e6%b3%95%e5%87%b8%e6%98%be%e9%ab%98%e8%b4%a8%e9%87%8f%e8%af%8a%e6%96%ad%e9%9c%80%e6%b1%82\/"},"modified":"2026-03-04T10:14:44","modified_gmt":"2026-03-04T10:14:44","slug":"emerging-haemophilia-therapies-highlight-a-need-for-quality-diagnostics","status":"publish","type":"acf_article","link":"https:\/\/labinsights.com\/zhcn\/disease-area\/rare-diseases\/emerging-haemophilia-therapies-highlight-a-need-for-quality-diagnostics\/","title":{"rendered":"\u65b0\u5174\u8840\u53cb\u75c5\u7597\u6cd5\u51f8\u663e\u9ad8\u8d28\u91cf\u8bca\u65ad\u9700\u6c42"},"content":{"rendered":"<p class=\"text-align-justify\">\u672c\u6587\u662f\u8840\u53cb\u75c5\u8bca\u65ad\u4e0e\u6cbb\u7597\u7cfb\u5217\u7684\u7b2c\u4e8c\u7bc7\u3002\u7b2c\u4e00\u7bc7\u6587\u7ae0(\u53ef\u5728 <a href=\"https:\/\/labinsights.com\/zhcn\/disease-area\/rare-diseases\/haemophilia-diagnostics-and-therapeutics-a-brief-introduction\/\">\u6b64\u5904<\/a>\u67e5\u770b)\u6982\u8ff0\u4e86\u8be5\u75be\u75c5\u7684\u4e34\u5e8a\u8868\u73b0\u3001\u8bca\u65ad\u548c\u6cbb\u7597\u65b9\u6cd5\u3002<\/p>\n<p class=\"text-align-justify\">\u968f\u7740\u7814\u7a76\u4eba\u5458\u5f00\u53d1\u51fa\u8840\u53cb\u75c5\u521b\u65b0\u7597\u6cd5\uff0c\u4e34\u5e8a\u5b9e\u9a8c\u5ba4\u4e13\u4e1a\u4eba\u5458\u5e94\u5173\u6ce8\u8fd9\u4e9b\u8fdb\u5c55\u53ca\u5176\u5bf9\u8bca\u65ad\u6d41\u7a0b\u7684\u6f5c\u5728\u5f71\u54cd\u3002\u672c\u6587\u5c06\u63a2\u8ba8\u90e8\u5206\u65b0\u5174\u6cbb\u7597\u65b9\u5f0f\u53ca\u5176\u5bf9\u68c0\u9a8c\u533b\u5b66\u7684\u5f71\u54cd\u3002<\/p>\n<h2 class=\"text-align-justify\" style=\"font-family: Inter !important; font-weight: 500 !important; font-size: 28px !important; line-height: 36px !important; letter-spacing: 0px !important;\">\u8840\u53cb\u75c5\u6709\u54ea\u4e9b\u65b0\u5174\u7597\u6cd5\uff1f<\/h2>\n<p class=\"text-align-justify\">\u73b0\u4ee3\u6cbb\u7597\u4ee5\u66ff\u4ee3\u7597\u6cd5\u4e3a\u6838\u5fc3\uff0c\u901a\u8fc7\u8f93\u6ce8\u51dd\u8840\u56e0\u5b50\u6d53\u7f29\u5242\u8865\u5145\u60a3\u8005\u8840\u6db2\u6210\u5206\u3002\u8fd9\u4e9b\u6cbb\u7597\u53ef\u80fd\u5bfc\u81f4\u5e76\u53d1\u75c7\uff0c\u4f8b\u5982\u4ea7\u751f\u4e2d\u548c\u6297\u4f53\uff08\u6291\u5236\u5242\uff09\u653b\u51fb\u8840\u6db2\u4e2d\u7684\u51dd\u8840\u56e0\u5b50\uff0c\u5bfc\u81f4\u8840\u53cb\u75c5\u53d1\u75c5\u7387\u5347\u9ad8[1]\u3002<\/p>\n<p class=\"text-align-justify\">\u4e3a\u89e3\u51b3\u8fd9\u4e9b\u95ee\u9898\u53ca\u5176\u4ed6\u6311\u6218\uff0c\u533b\u7597\u4e13\u4e1a\u4eba\u5458\u6b63\u5728\u63a2\u7d22\u591a\u79cd\u8840\u53cb\u75c5\u6cbb\u7597\u65b0\u65b9\u6cd5\uff0c\u5305\u62ec\u5ef6\u957f\u534a\u8870\u671f\uff08EHL\uff09\u51dd\u8840\u56e0\u5b50\u3001\u9776\u5411\u7ec4\u7ec7\u56e0\u5b50\u9014\u5f84\u6291\u5236\u7269\uff08TFPI\uff09\u7684\u5355\u514b\u9686\u6297\u4f53\u3001\u4f5c\u4e3a\u975e\u56e0\u5b50\u66ff\u4ee3\u7597\u6cd5\u7684\u53cc\u7279\u5f02\u6027\u6297\u4f53\uff0c\u4ee5\u53ca\u6709\u671b\u6cbb\u6108\u8be5\u75c5\u7684\u57fa\u56e0\u7597\u6cd5\u3002<\/p>\n<p class=\"text-align-justify\"><strong>\u5ef6\u957f\u534a\u8870\u671f\u51dd\u8840\u56e0\u5b50<\/strong><\/p>\n<p class=\"text-align-justify\">\u81ea2010\u5e74\u4ee3\u4ee5\u6765\uff0c\u91cd\u7ec4\u6280\u672f\u88ab\u7528\u4e8e\u6539\u9020\u51dd\u8840\u56e0\u5b50\u4ee5\u5ef6\u957f\u5176\u5faa\u73af\u65f6\u95f4\uff0c\u4ece\u800c\u964d\u4f4e\u7ed9\u836f\u9891\u7387[2]\u3002\u76ee\u524d\u5df2\u6709EHL FVIII\u548cFXI\u4ea7\u54c1\u4e0a\u5e02\u3002\u5404\u7c7bEHL\u4ea7\u54c1\u7684\u836f\u4ee3\u52a8\u529b\u5b66\u548c\u7597\u6548\u5df2\u5f97\u5230\u5145\u5206\u9a8c\u8bc1\uff0c\u5c24\u5176\u5728\u9884\u9632\u548c\u6cbb\u7597\u51fa\u8840\u65b9\u9762\u3002<\/p>\n<p class=\"text-align-justify\"><strong>\u9776\u5411\u7ec4\u7ec7\u56e0\u5b50\u9014\u5f84\u6291\u5236\u7269\uff08TFPI\uff09\u7684\u5355\u514b\u9686\u6297\u4f53<\/strong><\/p>\n<p class=\"text-align-justify\">\u9488\u5bf9TFPI\u6291\u5236\u5242\u7684\u5355\u514b\u9686\u6297\u4f53\u591a\u9879\u7814\u7a76\u6b63\u5728\u8fdb\u884c\uff0c\u8fd9\u7c7b\u836f\u7269\u6709\u671b\u589e\u5f3a\u6b62\u8840\u6d3b\u6027\u3001\u5f62\u6210\u66f4\u7a33\u5b9a\u7684\u8840\u6813\uff0c\u4ece\u800c\u51cf\u5c11\u51fa\u8840\u4e8b\u4ef6\u3002\u4ee3\u8868\u6027\u836f\u7269concizumab\u662f\u4e00\u79cd\u4eba\u6e90\u5355\u514b\u9686\u6297\u4f53\uff0c\u6b63\u5728\u8840\u53cb\u75c5A\/B\u60a3\u8005\u4e2d\u8fdb\u884cII\u671f\u4e34\u5e8a\u8bd5\u9a8c\u3002\u00a0\u6b27\u76df\u3001\u82f1\u56fd\u548c\u7f8e\u56fd\u9884\u8ba1\u5c06\u4e8e2023\/4\u5e74\u6279\u51c6\u8be5\u836f\u7528\u4e8e\u8840\u53cb\u75c5A\/B\u6cbb\u7597\u3002\u00a0 \u53e6\u4e00\u6b3e\u4e0econcizumab\u76f8\u4f3c\u7684\u5355\u6297BAY1093884\u4e5f\u6b63\u5728\u5f00\u5c55I\u671f\u4e34\u5e8a\u8bd5\u9a8c\u62db\u52df\u3002<\/p>\n<p class=\"text-align-justify\"><strong>\u4f5c\u4e3a\u975e\u56e0\u5b50\u66ff\u4ee3\u7597\u6cd5\u7684\u53cc\u7279\u5f02\u6027\u6297\u4f53<\/strong><\/p>\n<p class=\"text-align-justify\">\u5176\u4ed6\u65b0\u5174\u7597\u6cd5\u5305\u62ec\u975e\u56e0\u5b50\u66ff\u4ee3\u4ea7\u54c1\u3002\u8fd9\u7c7b\u836f\u7269\u591a\u4e3a\u53cc\u7279\u5f02\u6027\u6297\u4f53\uff08\u5982\u827e\u7f8e\u8d5b\u73e0\u5355\u6297\uff09\uff0c\u53ef\u6a21\u62df\u51dd\u8840\u56e0\u5b50\u529f\u80fd\uff0c\u6709\u6548\u6865\u63a5FXIa\u4e0eFX\u3002\u00a0\u827e\u7f8e\u8d5b\u73e0\u5355\u6297\u9002\u7528\u4e8e\u542bFVIII\u6291\u5236\u7269\u7684\u6210\u4eba\u548c\u513f\u7ae5\u60a3\u8005\u7684\u5e38\u89c4\u9884\u9632\u30022018\u5e744\u6708\uff0c\u8be5\u836f\u83b7\u5f97\u8840\u53cb\u75c5A\u7a81\u7834\u6027\u7597\u6cd5\u8ba4\u5b9a[3]\u3002<\/p>\n<p class=\"text-align-justify\"><strong>\u6709\u671b\u6cbb\u6108\u75be\u75c5\u7684\u57fa\u56e0\u7597\u6cd5<\/strong><\/p>\n<p class=\"text-align-justify\">\u6b64\u5916\uff0c\u57fa\u56e0\u7597\u6cd5\u4f5c\u4e3a\u6f5c\u5728\u6cbb\u6108\u65b9\u6848\u6b63\u5728\u7814\u7a76\u4e2d\u30022022\u5e745\u670824\u65e5\uff0cFDA\u53d7\u7406\u4e86\u8840\u53cb\u75c5B\u57fa\u56e0\u7597\u6cd5etranacogene dezaparvovec\u7684\u4f18\u5148\u5ba1\u8bc4\u7533\u8bf7[4]\u30022022\u5e746\u670824\u65e5\uff0c\u6b27\u6d32\u836f\u7ba1\u5c40\u5efa\u8bae\u6709\u6761\u4ef6\u6279\u51c6valoctocogene roxaparvovec\u7528\u4e8e\u6cbb\u7597\u4e0d\u542bFVIII\u6291\u5236\u7269\u7684\u91cd\u578b\u8840\u53cb\u75c5A\u60a3\u8005\u3002\u76ee\u524d\u6b63\u7b49\u5f85\u6b27\u76df\u59d4\u5458\u4f1a\u4f5c\u51fa\u6279\u51c6\u51b3\u5b9a[5]\u3002<\/p>\n<h2 class=\"text-align-justify\" style=\"font-family: Inter !important; font-weight: 500 !important; font-size: 28px !important; line-height: 36px !important; letter-spacing: 0px !important;\">\u8fd9\u5bf9\u5b9e\u9a8c\u5ba4\u8bca\u65ad\u610f\u5473\u7740\u4ec0\u4e48\uff1f<\/h2>\n<p class=\"text-align-justify\">\u4e34\u5e8a\u5b9e\u9a8c\u5ba4\u8bca\u65ad\u5728\u76d1\u6d4b\u4e0d\u540c\u8840\u53cb\u75c5\u7597\u6cd5\u7597\u6548\u65b9\u9762\u5177\u6709\u91cd\u8981\u4f5c\u7528\u3002\u4ee5\u66ff\u4ee3\u7597\u6cd5\u4e3a\u4f8b\uff0c\u51dd\u8840\u56e0\u5b50\u6d53\u7f29\u5242\u7684\u9009\u62e9\u81f3\u5173\u91cd\u8981\uff0c\u56e0\u5176\u76f4\u63a5\u5f71\u54cd\u68c0\u6d4b\u65b9\u6cd5\u7684\u9009\u62e9\u3002<\/p>\n<p class=\"text-align-justify\">\u968f\u7740\u827e\u7f8e\u8d5b\u73e0\u5355\u6297\u7b49\u975e\u56e0\u5b50\u7597\u6cd5\u7684\u5f15\u5165\uff0c\u5b9e\u9a8c\u5ba4\u9996\u5148\u9700\u8981\u7406\u89e3\u4e0d\u540c\u68c0\u6d4b\u65b9\u6cd5\u5bf9\u5e94\u7684\u836f\u7269\u4f5c\u7528\u673a\u5236\u548c\u751f\u5316\u5f71\u54cd\u3002\u8fdb\u800c\u624d\u80fd\u9009\u62e9\u6700\u5408\u9002\u7684\u76d1\u6d4b\u65b9\u6848\uff1a<\/p>\n<p class=\"text-align-justify\">\u65e0\u8bba\u91c7\u7528\u4f55\u79cd\u7597\u6cd5\uff0c\u6291\u5236\u5242\u4ea7\u751f\u7684\u53ef\u80fd\u6027\u59cb\u7ec8\u5b58\u5728\u3002\u4e34\u5e8a\u5b9e\u9a8c\u5ba4\u9700\u76d1\u6d4b\u6291\u5236\u7269\u7684\u4ea7\u751f\u60c5\u51b5\uff0c\u56e0\u5176\u4f1a\u5f71\u54cd\u6cbb\u7597\u6548\u679c\u3002\u4ee5\u4e0b\u662f\u6291\u5236\u7269\u68c0\u6d4b\u7684\u6ce8\u610f\u4e8b\u9879\u3002<\/p>\n<p class=\"text-align-justify\">\u5c3d\u7ba1\u76ee\u524d\u8840\u6d46\u6765\u6e90\u548c\u91cd\u7ec4\u56e0\u5b50\u4ea7\u54c1\u7684\u66ff\u4ee3\u7597\u6cd5\u4ecd\u662f\u8840\u53cb\u75c5\u4e3b\u8981\u6cbb\u7597\u624b\u6bb5\uff0c\u4f46\u9488\u5bf9\u65b0\u836f\u7814\u53d1\u7684\u7a81\u7834\u6027\u7814\u7a76\u5df2\u53d6\u5f97\u663e\u8457\u8fdb\u5c55\u3002\u8fd9\u4e9b\u65b0\u836f\u4f5c\u7528\u4e8e\u51dd\u8840\u7ea7\u8054\u53cd\u5e94\u4e2d\u4e0d\u540c\u7684\u5206\u5b50\u9776\u70b9\u3001\u57fa\u56e0\u548c\u86cb\u767d\u8d28\u3002\u7814\u7a76\u7ed3\u679c\u5408\u7406\u8868\u660e\uff0c\u8840\u53cb\u75c5\u7684\u6cbb\u6108\u4e4b\u8def\u6216\u5c06\u5728\u4e0d\u8fdc\u7684\u672a\u6765\u6210\u4e3a\u73b0\u5b9e[6]\u3002<\/p>\n<p class=\"text-align-justify\"><em>\u53c2\u8003\u6587\u732e\uff1a<\/em><\/p>\n<p class=\"text-align-justify\"><a href=\"https:\/\/www.cdc.gov\/ncbddd\/hemophilia\/inhibitors.html\" target=\"_blank\" rel=\"noopener\">[1]<\/a> \u7f8e\u56fd\u75be\u75c5\u63a7\u5236\u4e0e\u9884\u9632\u4e2d\u5fc3\uff0c\u8840\u53cb\u75c5\u4e3b\u9875-\u6291\u5236\u5242\u4e0e\u8840\u53cb\u75c5 https:\/\/www.cdc.gov\/ncbddd\/hemophilia\/inhibitors.html [2] Mannucci, P., 2020.<\/p>\n<p class=\"text-align-justify\"><a href=\"https:\/\/haematologica.org\/article\/view\/9274\" target=\"_blank\" rel=\"noopener\">[2]<\/a> Mannucci, P., 2020. Hemophilia therapy: the future has begun.Haematologica, 105(3), pp.545-553.<\/p>\n<p class=\"text-align-justify\"><a href=\"https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-emicizumab-kxwh-prevention-and-reduction-bleeding-patients-hemophilia-factor-viii\" target=\"_blank\" rel=\"noopener\">[3]<\/a> FDA approves emicizumab-kxwh for prevention and reduction of bleeding in patients with hemophilia A with factor VIII inhibitors. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-emicizumab-kxwh-prevention-and-reduction-bleeding-patients-hemophilia-factor-viii<\/p>\n<p class=\"text-align-justify\"><a href=\"https:\/\/www.fiercebiotech.com\/biotech\/2020-trial-pause-isnt-holding-csl-behring-back-fda-oks-priority-review-application\" target=\"_blank\" rel=\"noopener\">[4]<\/a> CSL Behring gene therapy makes comeback after hold for FDA priority review. https:\/\/www.fiercebiotech.com\/biotech\/2020-trial-pause-isnt-holding-csl-behring-back-fda-oks-priority-review-application<\/p>\n<p class=\"text-align-justify\"><a href=\"https:\/\/www.fiercepharma.com\/pharma\/biomarins-hemophilia-gene-therapy-roctavian-wins-conditional-eu-backing-fda-plan-delayed\" target=\"_blank\" rel=\"noopener\">[5]<\/a> BioMarin\u2019s haemophilia gene therapy Roctavian wins conditional EU backing amid FDA delay. https:\/\/www.fiercepharma.com\/pharma\/biomarins-hemophilia-gene-therapy-roctavian-wins-conditional-eu-backing-fda-plan-delayed<\/p>\n<p class=\"text-align-justify\"><a href=\"https:\/\/www1.wfh.org\/publications\/files\/pdf-1863.pdf\" target=\"_blank\" rel=\"noopener\">[6] <\/a>World Federation of Haemophilia Guidelines for the Management of Haemophilia. https:\/\/www1.wfh.org\/publications\/files\/pdf-1863.pdf<\/p>\n<p class=\"text-align-justify\">[7] National Haemophilia Foundation for all bleeding disorders-current treatments. https:\/\/www.hemophilia.org\/bleeding-disorders-a-z\/treatment\/current-treatments<\/p>\n<p class=\"text-align-justify\"><a href=\" https:\/\/www1.wfh.org\/publications\/files\/pdf-1863.pdf\">[8]<\/a> World Federation of Haemophilia Guidelines for the Management of Haemophilia. https:\/\/www1.wfh.org\/publications\/files\/pdf-1863.pdf<\/p>\n","protected":false},"excerpt":{"rendered":"<p>\u672c\u6587\u662f\u8840\u53cb\u75c5\u8bca\u65ad\u4e0e\u6cbb\u7597\u7cfb\u5217\u7684\u7b2c\u4e8c\u7bc7\u3002\u7b2c\u4e00\u7bc7\u6587\u7ae0(\u53ef\u5728 \u6b64\u5904\u67e5\u770b)\u6982\u8ff0\u4e86\u8be5\u75be\u75c5\u7684\u4e34\u5e8a\u8868\u73b0\u3001\u8bca\u65ad\u548c\u6cbb\u7597\u65b9\u6cd5\u3002 \u968f\u7740\u7814\u7a76\u4eba\u5458\u5f00\u53d1\u51fa\u8840\u53cb\u75c5\u521b\u65b0\u7597\u6cd5\uff0c\u4e34\u5e8a\u5b9e\u9a8c\u5ba4\u4e13\u4e1a\u4eba\u5458\u5e94\u5173\u6ce8\u8fd9\u4e9b\u8fdb\u5c55\u53ca\u5176\u5bf9\u8bca\u65ad\u6d41\u7a0b\u7684\u6f5c\u5728\u5f71\u54cd\u3002\u672c\u6587\u5c06\u63a2\u8ba8\u90e8\u5206\u65b0\u5174\u6cbb\u7597\u65b9\u5f0f\u53ca\u5176\u5bf9\u68c0\u9a8c\u533b\u5b66\u7684\u5f71\u54cd\u3002 \u8840\u53cb\u75c5\u6709\u54ea\u4e9b\u65b0\u5174\u7597\u6cd5\uff1f \u73b0\u4ee3\u6cbb\u7597\u4ee5\u66ff\u4ee3\u7597\u6cd5\u4e3a\u6838\u5fc3\uff0c\u901a\u8fc7\u8f93\u6ce8\u51dd\u8840\u56e0\u5b50\u6d53\u7f29\u5242\u8865\u5145\u60a3\u8005\u8840\u6db2\u6210\u5206\u3002\u8fd9\u4e9b\u6cbb\u7597\u53ef\u80fd\u5bfc\u81f4\u5e76\u53d1\u75c7\uff0c\u4f8b\u5982\u4ea7\u751f\u4e2d\u548c\u6297\u4f53\uff08\u6291\u5236\u5242\uff09\u653b\u51fb\u8840\u6db2\u4e2d\u7684\u51dd\u8840\u56e0\u5b50\uff0c\u5bfc\u81f4\u8840\u53cb\u75c5\u53d1\u75c5\u7387\u5347\u9ad8[1]\u3002 \u4e3a\u89e3\u51b3\u8fd9\u4e9b\u95ee\u9898\u53ca\u5176\u4ed6\u6311\u6218\uff0c\u533b\u7597\u4e13\u4e1a\u4eba\u5458\u6b63\u5728\u63a2\u7d22\u591a\u79cd\u8840\u53cb\u75c5\u6cbb\u7597\u65b0\u65b9\u6cd5\uff0c\u5305\u62ec\u5ef6\u957f\u534a\u8870\u671f\uff08EHL\uff09\u51dd\u8840\u56e0\u5b50\u3001\u9776\u5411\u7ec4\u7ec7\u56e0\u5b50\u9014\u5f84\u6291\u5236\u7269\uff08TFPI\uff09\u7684\u5355\u514b\u9686\u6297\u4f53\u3001\u4f5c\u4e3a\u975e\u56e0\u5b50\u66ff\u4ee3\u7597\u6cd5\u7684\u53cc\u7279\u5f02\u6027\u6297\u4f53\uff0c\u4ee5\u53ca\u6709\u671b\u6cbb\u6108\u8be5\u75c5\u7684\u57fa\u56e0\u7597\u6cd5\u3002 \u5ef6\u957f\u534a\u8870\u671f\u51dd\u8840\u56e0\u5b50 \u81ea2010\u5e74\u4ee3\u4ee5\u6765\uff0c\u91cd\u7ec4\u6280\u672f\u88ab\u7528\u4e8e\u6539\u9020\u51dd\u8840\u56e0\u5b50\u4ee5\u5ef6\u957f\u5176\u5faa\u73af\u65f6\u95f4\uff0c\u4ece\u800c\u964d\u4f4e\u7ed9\u836f\u9891\u7387[2]\u3002\u76ee\u524d\u5df2\u6709EHL FVIII\u548cFXI\u4ea7\u54c1\u4e0a\u5e02\u3002\u5404\u7c7bEHL\u4ea7\u54c1\u7684\u836f\u4ee3\u52a8\u529b\u5b66\u548c\u7597\u6548\u5df2\u5f97\u5230\u5145\u5206\u9a8c\u8bc1\uff0c\u5c24\u5176\u5728\u9884\u9632\u548c\u6cbb\u7597\u51fa\u8840\u65b9\u9762\u3002 \u9776\u5411\u7ec4\u7ec7\u56e0\u5b50\u9014\u5f84\u6291\u5236\u7269\uff08TFPI\uff09\u7684\u5355\u514b\u9686\u6297\u4f53 \u9488\u5bf9TFPI\u6291\u5236\u5242\u7684\u5355\u514b\u9686\u6297\u4f53\u591a\u9879\u7814\u7a76\u6b63\u5728\u8fdb\u884c\uff0c\u8fd9\u7c7b\u836f\u7269\u6709\u671b\u589e\u5f3a\u6b62\u8840\u6d3b\u6027\u3001\u5f62\u6210\u66f4\u7a33\u5b9a\u7684\u8840\u6813\uff0c\u4ece\u800c\u51cf\u5c11\u51fa\u8840\u4e8b\u4ef6\u3002\u4ee3\u8868\u6027\u836f\u7269concizumab\u662f\u4e00\u79cd\u4eba\u6e90\u5355\u514b\u9686\u6297\u4f53\uff0c\u6b63\u5728\u8840\u53cb\u75c5A\/B\u60a3\u8005\u4e2d\u8fdb\u884cII\u671f\u4e34\u5e8a\u8bd5\u9a8c\u3002\u00a0\u6b27\u76df\u3001\u82f1\u56fd\u548c\u7f8e\u56fd\u9884\u8ba1\u5c06\u4e8e2023\/4\u5e74\u6279\u51c6\u8be5\u836f\u7528\u4e8e\u8840\u53cb\u75c5A\/B\u6cbb\u7597\u3002\u00a0 \u53e6\u4e00\u6b3e\u4e0econcizumab\u76f8\u4f3c\u7684\u5355\u6297BAY1093884\u4e5f\u6b63\u5728\u5f00\u5c55I\u671f\u4e34\u5e8a\u8bd5\u9a8c\u62db\u52df\u3002 \u4f5c\u4e3a\u975e\u56e0\u5b50\u66ff\u4ee3\u7597\u6cd5\u7684\u53cc\u7279\u5f02\u6027\u6297\u4f53 \u5176\u4ed6\u65b0\u5174\u7597\u6cd5\u5305\u62ec\u975e\u56e0\u5b50\u66ff\u4ee3\u4ea7\u54c1\u3002\u8fd9\u7c7b\u836f\u7269\u591a\u4e3a\u53cc\u7279\u5f02\u6027\u6297\u4f53\uff08\u5982\u827e\u7f8e\u8d5b\u73e0\u5355\u6297\uff09\uff0c\u53ef\u6a21\u62df\u51dd\u8840\u56e0\u5b50\u529f\u80fd\uff0c\u6709\u6548\u6865\u63a5FXIa\u4e0eFX\u3002\u00a0\u827e\u7f8e\u8d5b\u73e0\u5355\u6297\u9002\u7528\u4e8e\u542bFVIII\u6291\u5236\u7269\u7684\u6210\u4eba\u548c\u513f\u7ae5\u60a3\u8005\u7684\u5e38\u89c4\u9884\u9632\u30022018\u5e744\u6708\uff0c\u8be5\u836f\u83b7\u5f97\u8840\u53cb\u75c5A\u7a81\u7834\u6027\u7597\u6cd5\u8ba4\u5b9a[3]\u3002 \u6709\u671b\u6cbb\u6108\u75be\u75c5\u7684\u57fa\u56e0\u7597\u6cd5 \u6b64\u5916\uff0c\u57fa\u56e0\u7597\u6cd5\u4f5c\u4e3a\u6f5c\u5728\u6cbb\u6108\u65b9\u6848\u6b63\u5728\u7814\u7a76\u4e2d\u30022022\u5e745\u670824\u65e5\uff0cFDA\u53d7\u7406\u4e86\u8840\u53cb\u75c5B\u57fa\u56e0\u7597\u6cd5etranacogene dezaparvovec\u7684\u4f18\u5148\u5ba1\u8bc4\u7533\u8bf7[4]\u30022022\u5e746\u670824\u65e5\uff0c\u6b27\u6d32\u836f\u7ba1\u5c40\u5efa\u8bae\u6709\u6761\u4ef6\u6279\u51c6valoctocogene roxaparvovec\u7528\u4e8e\u6cbb\u7597\u4e0d\u542bFVIII\u6291\u5236\u7269\u7684\u91cd\u578b\u8840\u53cb\u75c5A\u60a3\u8005\u3002\u76ee\u524d\u6b63\u7b49\u5f85\u6b27\u76df\u59d4\u5458\u4f1a\u4f5c\u51fa\u6279\u51c6\u51b3\u5b9a[5]\u3002 \u8fd9\u5bf9\u5b9e\u9a8c\u5ba4\u8bca\u65ad\u610f\u5473\u7740\u4ec0\u4e48\uff1f \u4e34\u5e8a\u5b9e\u9a8c\u5ba4\u8bca\u65ad\u5728\u76d1\u6d4b\u4e0d\u540c\u8840\u53cb\u75c5\u7597\u6cd5\u7597\u6548\u65b9\u9762\u5177\u6709\u91cd\u8981\u4f5c\u7528\u3002\u4ee5\u66ff\u4ee3\u7597\u6cd5\u4e3a\u4f8b\uff0c\u51dd\u8840\u56e0\u5b50\u6d53\u7f29\u5242\u7684\u9009\u62e9\u81f3\u5173\u91cd\u8981\uff0c\u56e0\u5176\u76f4\u63a5\u5f71\u54cd\u68c0\u6d4b\u65b9\u6cd5\u7684\u9009\u62e9\u3002 \u968f\u7740\u827e\u7f8e\u8d5b\u73e0\u5355\u6297\u7b49\u975e\u56e0\u5b50\u7597\u6cd5\u7684\u5f15\u5165\uff0c\u5b9e\u9a8c\u5ba4\u9996\u5148\u9700\u8981\u7406\u89e3\u4e0d\u540c\u68c0\u6d4b\u65b9\u6cd5\u5bf9\u5e94\u7684\u836f\u7269\u4f5c\u7528\u673a\u5236\u548c\u751f\u5316\u5f71\u54cd\u3002\u8fdb\u800c\u624d\u80fd\u9009\u62e9\u6700\u5408\u9002\u7684\u76d1\u6d4b\u65b9\u6848\uff1a \u65e0\u8bba\u91c7\u7528\u4f55\u79cd\u7597\u6cd5\uff0c\u6291\u5236\u5242\u4ea7\u751f\u7684\u53ef\u80fd\u6027\u59cb\u7ec8\u5b58\u5728\u3002\u4e34\u5e8a\u5b9e\u9a8c\u5ba4\u9700\u76d1\u6d4b\u6291\u5236\u7269\u7684\u4ea7\u751f\u60c5\u51b5\uff0c\u56e0\u5176\u4f1a\u5f71\u54cd\u6cbb\u7597\u6548\u679c\u3002\u4ee5\u4e0b\u662f\u6291\u5236\u7269\u68c0\u6d4b\u7684\u6ce8\u610f\u4e8b\u9879\u3002 \u5c3d\u7ba1\u76ee\u524d\u8840\u6d46\u6765\u6e90\u548c\u91cd\u7ec4\u56e0\u5b50\u4ea7\u54c1\u7684\u66ff\u4ee3\u7597\u6cd5\u4ecd\u662f\u8840\u53cb\u75c5\u4e3b\u8981\u6cbb\u7597\u624b\u6bb5\uff0c\u4f46\u9488\u5bf9\u65b0\u836f\u7814\u53d1\u7684\u7a81\u7834\u6027\u7814\u7a76\u5df2\u53d6\u5f97\u663e\u8457\u8fdb\u5c55\u3002\u8fd9\u4e9b\u65b0\u836f\u4f5c\u7528\u4e8e\u51dd\u8840\u7ea7\u8054\u53cd\u5e94\u4e2d\u4e0d\u540c\u7684\u5206\u5b50\u9776\u70b9\u3001\u57fa\u56e0\u548c\u86cb\u767d\u8d28\u3002\u7814\u7a76\u7ed3\u679c\u5408\u7406\u8868\u660e\uff0c\u8840\u53cb\u75c5\u7684\u6cbb\u6108\u4e4b\u8def\u6216\u5c06\u5728\u4e0d\u8fdc\u7684\u672a\u6765\u6210\u4e3a\u73b0\u5b9e[6]\u3002 \u53c2\u8003\u6587\u732e\uff1a [1] \u7f8e\u56fd\u75be\u75c5\u63a7\u5236\u4e0e\u9884\u9632\u4e2d\u5fc3\uff0c\u8840\u53cb\u75c5\u4e3b\u9875-\u6291\u5236\u5242\u4e0e\u8840\u53cb\u75c5 https:\/\/www.cdc.gov\/ncbddd\/hemophilia\/inhibitors.html [2] Mannucci, P., 2020. [2] Mannucci, P., 2020. Hemophilia therapy: the future has begun.Haematologica, 105(3), pp.545-553. [3] FDA approves emicizumab-kxwh for prevention and reduction of bleeding in patients [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":138766,"parent":0,"menu_order":0,"template":"","meta":{"_acf_changed":false,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"set","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"tags":[12372,14018],"pillarandcategory":[294,292,282],"reporter":[12558,12559],"class_list":["post-145644","acf_article","type-acf_article","status-publish","has-post-thumbnail","hentry","tag-12372","tag-14018","pillarandcategory-rare-diseases","pillarandcategory-coagulation","pillarandcategory-disease-area","reporter-niti-dawar","reporter-yingli-huang"],"acf":[],"_links":{"self":[{"href":"https:\/\/labinsights.com\/zhcn\/wp-json\/wp\/v2\/acf_article\/145644","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/labinsights.com\/zhcn\/wp-json\/wp\/v2\/acf_article"}],"about":[{"href":"https:\/\/labinsights.com\/zhcn\/wp-json\/wp\/v2\/types\/acf_article"}],"author":[{"embeddable":true,"href":"https:\/\/labinsights.com\/zhcn\/wp-json\/wp\/v2\/users\/1"}],"version-history":[{"count":4,"href":"https:\/\/labinsights.com\/zhcn\/wp-json\/wp\/v2\/acf_article\/145644\/revisions"}],"predecessor-version":[{"id":149749,"href":"https:\/\/labinsights.com\/zhcn\/wp-json\/wp\/v2\/acf_article\/145644\/revisions\/149749"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/labinsights.com\/zhcn\/wp-json\/wp\/v2\/media\/138766"}],"wp:attachment":[{"href":"https:\/\/labinsights.com\/zhcn\/wp-json\/wp\/v2\/media?parent=145644"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/labinsights.com\/zhcn\/wp-json\/wp\/v2\/tags?post=145644"},{"taxonomy":"pillarandcategory","embeddable":true,"href":"https:\/\/labinsights.com\/zhcn\/wp-json\/wp\/v2\/pillarandcategory?post=145644"},{"taxonomy":"reporter","embeddable":true,"href":"https:\/\/labinsights.com\/zhcn\/wp-json\/wp\/v2\/reporter?post=145644"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}